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Available online 3 April 2017Neutral Lipid Storage Disease with Myopathy (NLSDM) is a rare defect of triacylglycerol metabolism, character-
ized by the abnormal storage of neutral lipid in organelles known as lipid droplets (LDs). The main clinical fea-
tures are progressive myopathy and cardiomyopathy. The onset of NLSDM is caused by autosomal recessive
mutations in the PNPLA2 gene, which encodes adipose triglyceride lipase (ATGL). Despite its name, this enzyme
is present in a wide variety of cell types and catalyzes the first step in triacylglycerol lipolysis and the release of
fatty acids.
Here, we report the derivation of NLSDM-induced pluripotent stem cells (NLSDM-iPSCs) from fibroblasts of two
patients carrying different PNPLA2 mutations. The first patient was homozygous for the c.541delAC, while the
second was homozygous for the c.662GNC mutation in the PNPLA2 gene. We verified that the two types of
NLSDM-iPSCs possessed properties of embryonic-like stem cells and could differentiate into the three germ
layers in vitro. Immunofluorescence analysis revealed that iPSCs had an abnormal accumulation of triglycerides
in LDs, the hallmark of NLSDM. Furthermore, NLSDM-iPSCs were deficient in long chain fatty acid lipolysis,
when subjected to a pulse chase experiment with oleic acid. Collectively, these results demonstrate that
NLSDM-iPSCs are a promising in vitro model to investigate disease mechanisms and screen drug compounds
for NLSDM, a rare disease with few therapeutic options.emistry an
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Neutral Lipid Storage Disease with Myopathy (NLSDM; MIM
610717) is a rare autosomal recessive disorder characterized by an in-
creased accumulation of triacylglycerols (TAGs) in numerous tissues
(Fig. 1A and B). TAGs are the most common neutral lipids stored in
lipid droplets (LDs), the cytoplasmic organelles involved in lipidmetab-
olism. The major clinical features of NLSDM are a progressive skeletal
muscle myopathy, and elevated serum transaminases and creatine ki-
nase in N90% of NLSDM subjects [1–4]. Approximately 40% of patientsd Molecular Biology,
0145 Milan, Italy.
be considered as first
open access article underdevelop cardiomyopathy and in about 25% of them, the heart failure is
lethal [5–7]. In addition, NLSDM subjects can develop hepatomegaly
and diabetes [1,2,8]. The observation of lipid-containing vacuoles in leu-
kocytes, also known as Jordans' anomaly, is an essential step for the clin-
ical diagnosis [9] (Fig. 1A), whereas the presence of lipid inclusion in
muscle biopsies confirms the muscle involvement [8,10].
Mutations in the PNPLA2 gene are associated with this disorder [1].
The PNPLA2 gene encodes adipose triglyceride lipase (ATGL), a member
of the patatin-like phospholipase domain-containing protein family,
which catalyzes the first step in the hydrolysis of TAGs that are stored
within LDs. The ATGL protein consists of 504 amino acids divided into
an N-terminal part, containing the patatin domain, and a C-terminal
part, containing a LD-binding domain [1]. To date, 47 patients
harbouring 32 differentmutations have been reported [1,2,3,7,8,10–15].
NLSDM has been recognized only recently, and its clinical, genetic
and metabolic implications have not been completely elucidated.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Lipid droplets abnormal storage in different tissues of NLSDM patient 1, compared
to a control subject. (A) Buffy coats stained with May-Grünwald-Giemsa (arrow indicates
Jordans' anomaly in the granulocyte of patient 1). Magnification: 100×. (B) Phase contrast
images of primary dermal fibroblasts obtained from a control subject and NLSDM patient
(patient 1) whose fibroblasts were used to produce iPS cells. Arrows indicate abnormal
TAGs accumulation in the NLSDM fibroblasts. Magnification: 40×. (C) Direct sequencing
of PNPLA2 gene confirmed the presence of mutations in the two disease-specific iPSC
lines (c.541delAC and c.662GNC respectively).
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effect on enzyme activity has not been ascertained. Fibroblasts and
myocytes, obtained from patients, have been used as cellular models
to investigate the pathological mechanism and/or to test compounds
to treat this disorder [11]. However, the limited availability of relevant
human primary cell types such as myocytes and cardiomyocytes has
hampered the ability to adequately study pathways or to test potential
drug therapy.
Induced pluripotent stem cells (iPSCs) are a new technology which
can provide an unlimited number of human disease-affected stem
cells [16–21]. These cells can theoretically differentiate into any cell
type. iPSCs have been generated from human somatic cells and have
been used to investigate disease pathogenesis and to test new drugs
[22–25]. Although iPSCs have been generated asmodel for some storage
diseases (Pompe disease, Gaucher disease, Niemann-Pick Type C) [22,
26,27], NLSDM-iPSCs are not yet available.
Here, we describe the generation of NLSDM disease-specific human
iPSCs from fibroblasts of previously reported patients [2,3]. The firstpatient is amalewho is homozygous for c.541delAC PNPLA2 genemuta-
tion. This mutation is predicted to produce a truncated ATGL protein
(I212X) lacking the LD-binding domain. The second patient is homozy-
gous for the c.662GNC mutation. This mutation leads to the production
of ATGL protein with decreased lipase activity, but able to bind to LDs
[3]. In this paper we show that the iPS cells derived from these patients
possess hESC-like characteristics and that theNLSDM-iPSCs recapitulate
the disease phenotype of interest.
2. Material and methods
2.1. Reprogramming of human dermal fibroblasts into iPSCs
Dermal fibroblast samples were grown as previously described [3].
The enrolled subjects were 2 NLSDM patients [2,3] carrying different
mutations in the PNPLA2 gene and 2 healthy subjects. All participants
gave informed consent to donate skin samples for research purpose.
iPSCs were established by infecting 2 × 105 fibroblasts with the
Yamanaka reprogramming factors OCT4, SOX2, KLF4 and c-MYC
contained as separated Sendai-vectors into the CytoTune™-iPS Sendai
Reprogramming Kit (Life Technologies, Monza, Italy). Cells were main-
tained in standard growth media at 37 °C and 5% CO2. Our standard
growth media consisted of DMEM-F12 (Sigma Aldrich, Milan, Italy),
2 mM L-glutamine (Euroclone, Milan, Italy), 10% Fetal Bovine Serum
(FBS; GE Healthcare, Milan, Italy) and 1% penicillin/streptomycin
(Euroclone, Milan, Italy). After 5 days, the cells were split and re-plated
as single cells onto Matrigel coated multi-well plates (Corning, New
York, USA), 35 mmdiameter well, containing a MEF (mouse embryonic
fibroblast) feeder layer previously inactivated for 3 hwithMEFmedium
supplemented with 10 μg/mlmytomicin C (Mipharm SPA, Milan, Italy).
On day 7, the medium was changed to hESC medium consisting of
DMEM-F12, 20% Knockout serum replacement (KOSR; Life Technolo-
gies, Monza, Italy), 100 μMnon-essential amino acids (Millipore, Darm-
stadt, Germany), 10 ng/μl basic Fibroblast Growth Factor (bFGF; Life
Technologies,Monza, Italy), 1% penicillin/streptomycin, 1% L-glutamine,
1% sodium pyruvate (Sigma Aldrich, Milan, Italy) and 0.2% β-
mercaptoethanol (Millipore, Darmstadt, Germany). After 24–28 days,
colonies with compact human embryonic cell-like morphology were
observed and clonal lines were established by manually picking colo-
nies. Human iPSC lines were maintained with hESC medium replaced
daily. Expansion and splitting of the iPSC colonies was performed as
previously described [28] using exclusivemechanical action orwith col-
lagenase IV (Life Technology, Carlsbad, USA).
2.2. Karyotyping (Q-banding) of iPSC
About 5 × 104 cells (iPSCs of patient 1 at passage number 4; iPSCs of
patient 2 at passage number 5) per slide flask (Thermo Scientific/NUNC
75 mm × 25 mm) were cultured for 24 h in a 37 °C incubator with 5%
CO2. Colcemid solution (at a final concentration of 0.1 μg ml−1; Sigma
Aldrich,Milan, Italy)was added, and cellswere placed at 37 °C for an ad-
ditional 30 min to ensure cell cycle arrest at metaphase. The cells were
then treated with a hypotonic solution (KCl 1.33%; CarloErba Reagents
SAS, Val de Reuil, France) for 10 min and fixed using methanol:acetic
acid (3:1). The chromosomes were stained with quinacrine mustard
(DBA Italia, Segrate, Italy) and the QFQ banding was analyzed with a
Olympus BX-41 fluorescence microscope.
2.3. Pluripotency detection of iPSC lines derived from healthy subjects and
NLSDM patients
2.3.1. Stem cell markers
Morphologically intact iPSC colonies were subcloned by mechanical
picking, transferred to Matrigel coated slide flasks, and maintained for
1–2 dayswith hESCmedia. Cellswerefixed in 4% PFA-PBS and immuno-
stained using standardprotocols [26]. The cells (patient 1: 14th passage;
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following pluripotent markers: anti-OCT4 (Mouse mAb; Sigma Aldrich,
Milan, Italy), anti-SSEA-4 (Mouse mAb; Life Technology, Carlsbad, USA)
and anti-TRA-1-81 (Mouse mAb; Millipore, Darmstadt, Germany); the
nuclei were counter-stained with DAPI (working DAPI solution was
200 ng/ml; Sigma Aldrich, Milan, Italy) for 2 min. The secondary anti-
body used was goat-anti mouse Alexa 488 (Life Technologies, Monza,
Italy). The dilutions adopted were 1:200 for all primary antibodies and
1:1000 for the secondary antibody.
2.3.2. Real time qRT-PCR
For Real Time qRT-PCR analysis, cell lines collected from 35mmwell
were extractedwith Trizol reagent (Life Technologies,Monza, Italy), ac-
cording to the manufacturer's instructions. After treatment of 1 μg of
RNA with DNAse I (Roche, Basel, Switzerland), the sample was re-
verse-transcribed into first-strand cDNA using Advantage® RT-for-PCR
Kit (Diatech Lab Line Srl, Jesi, Italy). Reverse transcription was per-
formed with a mix of random primer and poly-dT using the following
protocol: incubation for 1 h at 42 °C, inactivation for 5 min at 94 °C,
and cooling to 4 °C. cDNA was quantified with NanoDrop ND-1000
Spectrophotometer (NanoDrop Technologies, Wilmington, USA) and
diluted to a concentration of 20 ng/μl. Real Time qRT-PCR with 40 ng
of cDNA in a 20 μl-reaction volume was carried out in triplicate using
Light Cycler 480 SYBR Green I Master (Roche, Basel, Switzerland) in
Light Cycler® 480 System (Roche, Basel, Switzerland) with the follow-
ing PCR program: 95 °C for 10 min, 45 cycles at 95 °C for 10 s, 62 °C
for 10 s, and 72 °C for 20 s. Primer sequences were reported in Table
1. Relative quantification was calculated using the 2−ΔΔCt method
after normalization with β-actin (ACTB) expression [29] and plotted to
the expression level in the fibroblast cell lines [30].
2.4. Triglyceride quantification in NLSDM and control iPSCs
NLSDMand control iPSCswere seeded onto plates 100mmdiameter
at a density of 1 × 106 cells/plate. The day after the cells were homoge-
nized in 1 ml solution containing 5% TRITON X-100 (Sigma-Aldrich,
Saint Louis, MO, USA), incubated at 80 °C for 5 min and centrifuged for
2 min. Cellular triglyceride content was quantified using Triglyceride
Quantification Colorimetric Kit (Biovision, Milpitas, CA, USA), according
to the instructions. The absorbancewasmeasured at 570 nmwith EnVi-
sion Multilabel Reader (PerkinElmer, Waltham, MA, USA).
2.5. Embryoid bodies (EBs) formation and in vitro differentiation of
NLSDM-iPSC
After treatment with collagenase at 1 mg/ml for 1h at 37°C, 2 wells
of iPSCs (80% confluent) were harvested and transferred onto 100 mm
ultra-low attachment dishes/bacteriological Petri Dishes (LP Italiana
SPA, Milan, Italy) in hESC medium without bFGF to promote EB forma-
tion. After growing in suspension for 5 days, the EBs were plated on a
Geltrex-coated culture (Life Technologies, Monza, Italy) slide flask
(75 mm× 25mm) for up to 20 days in DMEM containing 20% FBS [31].Table 1










TDGF1 GGATACCTGGCCTTCAGAGA CAGGCAGCAGGTTCTGTTTAAfter fixation in 4% PFA-PBS for 30 min, cells were characterized by
immunostaining for the expression of the lineagemarkers of endoderm
(rabbit anti-FOXA2, 1:500; ABcam, Cambridge, MA),mesoderm (mouse
Anti-Actin, α-Sma; 1:100; Life Technologies, Monza, Italy) and ecto-
derm (rabbit anti-TUJ1, 1:500; Life Technologies,Monza, Italy). The sec-
ondary antibodies (dilution 1:250) were AlexaFluor® 488 goat anti-
mouse (Life Technologies, Monza, Italy), AlexaFluor® 488 donkey
anti-rabbit (Life Technologies, Monza, Italy), and AlexaFluor® 594
goat anti-mouse (Life Technologies, Monza, Italy).
2.6. Oleic acid pulse-chase experiment
Control and NLSDM-iPSCs were seeded on slide flasks (75 mm
× 25mm) and grown in a hESCmedium, then incubated for 18 h in cul-
ture medium containing 200 μM oleic acid (OA/BSA). The next day, in
half of the slide flasks, the medium containing OA/BSA was removed
and the cells were fixed with 3% paraformaldehyde and labeled with
Nile Red (NR). NR solution was prepared in PBS (1:100 v/v) from a sat-
urated solution (1 mg/ml) dimethyl sulfoxide. After three rinses with
distilled water, the cells were incubated with NR solution for 20 min
in the dark and mounted with Vectashield mounting medium (Vector
Laboratories, Burligame, USA). iPSC colonies in the remaining slide
flasks were washed three times with PBS, and then incubated for 24
or 72 h in the hESC medium containing 5% KOSR and fatty acid-free
BSA (2% w/v) to enhance cellular lipolysis (chase). At the end of each
chase (24 h and 72 h), the medium was removed, and the cells were
stained with NR.2.7. Quantification of LDs number and dimension
Fluorescence images were captured with a Leica MB5000B micro-
scope. ‘WCIF ImageJ 1.35j’ software (developed byW. Rasband, NIH, Be-
thesda, MD, USA) was used to isolate components having the same
wavelength and to quantify some parameters like area and number of
selected units (lipid droplets, in this specific case) in control and pa-
tients iPSCs lines. The statistical analysis of quantitative data of LDs
identified from iPSCs by image analysis of immunofluorescent experi-
ments was made using SPSS v.19 package (SPSS, Chigaco, IL, USA). The
valueswere compared using Student t-test. A P-value of b0.05was con-
sidered to be statistically significant.3. Results
3.1. Derivation and characterization of NLSDM-iPSCs
To generate iPSCs, dermal fibroblasts from two NLSDM patients and
two control subjects were transduced with Sendai virus encoding for
OCT4, SOX2, KLF4 and c-MYC. After about 4 weeks, the pluripotent
properties of iPSCs of some NLSDM and control colonies were deter-
mined. Karyogram showed a normal 46,XY karyotype of controls and
NLSDM-iPSCs (data not shown) and genomic sequencing analysis con-
firmed that NLSDM-iPSC lines still contained the disease-specific muta-
tions of PNPLA2 gene (c.541delAC and c.662GNC) (Fig. 1C). To
determine whether the fibroblasts were efficiently reprogrammed
into iPSCs, the expression of pluripotent markers was evaluated by im-
munofluorescence and qRT-PCR analysis. Immunofluorescence assays
versusOCT4, SSEA4 and TRA-1-81 confirmed the stemness gene expres-
sion profile (Fig. 2A). In agreement, qRT-PCR analysis indicated that
NLSDM-iPSC lines, as compared to the patient fibroblast cell lines,
show an increased expression of all 8 pluripotency-associated genes
(ZFP42, SOX2, POU5F1 alias OCT4, hTERT, LIN28A, DPPA2, NANOG and
TDGF1) (Fig. 2B). The increased expression was ranging from about
100 times (DPPA2 gene) to 100,000 times (SOX2 gene). Finally, the
Fig. 2. Characterization and differentiation of patient-derivedNLSDM-iPSC. (A) Immunostainingwith primary antibodies anti-OCT4, anti-SSEA-4 and anti-TRA-1-81 revealed thatNLSDM-
iPSCs expressmarkers of pluripotency, including OCT4 (red), SSEA4 (green), and TRA-1-81 (green). Nuclei were stainedwith DAPI. Magnification: 10×. (B) Real-time quantitative RT-PCR
assays for eight pluripotency-associate genes in two patient-derived iPSCs compared with fibroblast cell lines (basal level reported as 1). Data represent the mean of three independent
experiments, performed in triplicate. PCR reactions were normalized against an internal control (ACTB). (C) Quantification of TG content in iPSCs derived from 2 controls and 2 NLSDM
fibroblast cell lines. The graph represents TG content obtained from three independent experiments. The analysis was performed using Student t-test. Thick bar: mean value; error bar:
SD. P-values of b0.05 and of b0.01 were considered to be significant and indicated with “*”and “**”, respectively.
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mined in order to evaluate whether the NLSDM-iPSCs maintained the
defect of neutral lipid metabolism. As expected, the TG content of
NLSDM-iPSCs was significant higher than that of control iPSCs (Fig. 2C).3.2. Generation of EBs from NLSDM-iPSCs
To evaluate the in vitro differentiation of NLSDM-iPSC lines, the for-
mation of Embryoid Bodies (EBs) was promoted. After replating onto
32 D. Tavian et al. / Molecular Genetics and Metabolism 121 (2017) 28–34Geltrex-coated culture, the EBs spontaneously differentiated into cells
with varied morphology belonging to the three germ layers. Immuno-
fluorescence staining showed that the differentiated NLSDM-iPSCs
expressed forkhead box protein A2 (FOXA2, endoderm), α-smooth
muscle actin (α-SMA, mesoderm), and βIII-tubulin (TUJ1, ectoderm)
(Fig. 3).
3.3. Evaluation of NLSDM pathophysiological features in disease-specific
iPSCs
To assess whether the NLSDM-iPSCs expressed the pathological
characteristics of NLSDM, we compared the retention of TAGs in control
and NLSDM-iPSCs. After 3 days in culture, cells were stained with NR
and the LD number and dimensions were analyzed. Compared to con-
trol cells, the NLSDM-iPSCs had 20 times more LDs and almost 5-fold
larger LDs (Fig. 4A and B).
AnOApulse-chase experimentwas performed to confirm that lipase
activity is impaired in NLSDM-iPSCs compared to control cells (Fig. 4C
and D). When iPSCs were incubated for 18 h with 200 μM oleic acid
(OApulse) TAGs accumulated in cytoplasmic LDs of patients and control
iPSCs, as demonstrated by increased LDs number and size (Pulse: con-
trol-LDnumber = 45, iPSCs-LDnumber = 38, control-LDsize = 3 μm2,
iPSCs-LDsize = 2.9 μm2). In patients' cells, loss of lipid was almost
completely abrogated during the chase phase (medium with 5% KOSR
and fatty acid-free BSA-2% w/v), so that after 72 h, the patients' cells
showed little reduction in the number of LDs (Chase-72 h: iPSCs-
LDnumber = 28) and an insignificant reduction of LDs area (Chase-
72 h: iPSCs-LDsize = 2.7 μm2). In contrast, control iPSCs showed an al-
most complete loss of LDs during the chase (Chase-72 h: control-
LDnumber = 6, control-LDsize = 0,7 μm2) (Fig. 4C and D).
These results demonstrated that iPSCs recapitulate NLSDM specific-
lipid metabolism defects.
4. Discussion
In this study, we report the use of Sendai-based vectors to generate
iPSCs from two lines of NLSDM fibroblasts. The NLSDM-iPSC lines pos-
sess stem cells properties and are able to differentiate into three germ
layers. In addition, these iPSCs show an abnormal accumulation of neu-
tral lipids, a typical feature of neutral lipid storage disorder, caused by
partial or total abrogation of the lipolytic function of ATGL. Finally,
using an OA pulse-chase experiment, we demonstrate a strong impair-
ment in TAG lipase activity of NLSDM-iPSCs compared to control iPSCs,Fig. 3.NLSDM-iPSCs differentiation into all three embryonic germ layers in vitro. Immunostaini
for the three germ layers, endoderm-FOXA2, mesoderm-α-SMA and ectoderm-TUJ1, were expthus confirming the validity of NLSDM-iPSCs as biochemical disease
model.
Although the generation of iPSCs as cellular tool was reported for
some disorders [17–27], this is the first time that NLSDM-iPSCs have
been derived from fibroblasts of NLSDM patients. Cellular studies are
needed to understand the pathophysiological mechanism of NLSDM
and to develop personalized treatments that might increase fat mobili-
zation and improve organ function. Unfortunately, it is difficult to obtain
myocytes and to expand these cells in vitro. Moreover, it is even more
difficult to obtain cardiomyocytes from patients. Our data shows that
while maintaining NLSDM features, NLSDM-iPSCs can differentiate
into germ layers, including mesoderm cells, from which skeletal and
cardiac cells derive. Differentiation of NLSDM-iPS mesodermal cells
into skeletal myocytes and cardiomyocytes would present a model for
investigating cellular and molecular mechanisms that underlie the my-
opathy and cardiomyopathy of NLSDM patients. In addition, such cellu-
lar models would be useful in testing possible therapeutic agents.
Lipid-containing vacuoles in leukocytes (Jordans' anomaly) of
NLSDM patients are considered to be a hallmark of the disease [9]. The
diagnosis is then confirmed by the presence of abundant triacylglycerol
droplets in non-adipose cells [5–8,11,12,14] and finally by molecular
analysis of PNPLA2 gene mutations. However, clinical heterogeneity in
NLSDM patients has been reported, and on occasion, abnormal storage
of lipids in cytoplasmic LDs is detected before other clinical findings
have occurred [32]. In contrast, in some patients the abnormal storage
of lipid in cytoplasmic LDs is scarcely detected [4]. Hence, besides the
static morphological evaluation of cytoplasmic LD number and dimen-
sion, it would be useful to perform a functional-dynamic assay to test
cellular TAG lipase activity. As previously reported [3,33], the ability to
hydrolyze the TAGs stored in NLSDM fibroblasts can be tested using
OA in a pulse-chase assay. Our previous data showed that NLSDM fibro-
blasts were not able to mobilize LD lipids during the chase phase [3]. In
agreement, present data show that the OA pulse-chase experiment
might be a useful tool to assess impaired lipase activity in iPSCs obtained
from NLSDM patients.
5. Conclusion
We report the derivation of iPSCs from fibroblasts of two NLSDMpa-
tients carrying different ATGL mutations. These iPSCs exhibited defects
in neutral lipid metabolism similar to those of NLSDM fibroblasts.
NLSDM-iPSCs should be able to undergo directed differentiation into
cardiomyocytes and could be used to investigate the cellular andng using primary antibodies anti-FOXA2, anti-α-SMA and anti-TUJ1 showed that markers
ressed in differentiated NLSDM-iPSCs. Nuclei were stained with DAPI. Magnification: 20×.
Fig. 4. Evaluation of NLSDM pathophysiological characteristic in the disease-specific iPSCs. Nile Red stained microphotographs of control and NLSDM-iPSCs (A; magnification: 20×)
revealed more LDs (yellow) in the NLSDM cells. (B) Analysis of LD number and dimensions observed in NLSDM-iPSCs, compared to control iPSCs (n = 3; 100 cells were analyzed for
each experiment) was carried out by Student's t-test. Thick bar: mean value; error bar: SD. P-values of b0.05 and of b0.01 were considered to be significant and indicated with “*” and
“**”, respectively. (C) Oleic acid pulse-chase experiments on control and NLSDM-iPSCs. Culture medium (CM: DMEM-F12 containing 20% KOSR, 100 μM non-essential amino acids,
10 ng/ul bFGF, 1% penicillin/streptomycin, 1% L-glutamine, 1% sodium pyruvate and 0.2% β-mercaptoethanol) was supplemented with OA (200 μM) and, after 18 h, iPSCs were washed
and chased with fresh medium containing 5% KOSR and fatty acid free BSA (2% w/v) for 24 and 72 h. Cells were stained for neutral lipids with NR. Lipid droplets are in yellow.
Magnification: 40×. (D) Analysis of LD number and dimension observed in NLSDM-iPSCs, compared to control iPSCs, during the oleic acid pulse-chase experiments. In two
independent experiments 100 cells in each of 3 replicates were analyzed. Thick bar: mean value; error bar: SD. P-values of b0.05 and of b0.01 were considered to be significant and
indicated with “*”and “**”, respectively.
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